Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds
Rejection by insurers leaves patients and physicians frustrated, with few acceptable alternatives, says Matthew Budoff.
Stay updated with breaking news from Dianee Macdougall. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rejection by insurers leaves patients and physicians frustrated, with few acceptable alternatives, says Matthew Budoff.
A new study published in Circulation: Cardiovascular Quality and Outcomes from the Family Heart Foundation -; a patient-centered research and advocacy nonprofit organization dedicated to improving the lives of families impacted by inherited lipid disorders and LDL-cholesterol -; revealed that utilization of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to reduce low-density lipoprotein cholesterol (LDL-C) remains low among high-risk patients.